GODIVA: Grip on Knee Osteoarthritis; DIstraction Versus Arthroplasty

Sponsor
UMC Utrecht (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06113549
Collaborator
(none)
600
2
54

Study Details

Study Description

Brief Summary

The goal of this pragmatic, open, (1:1) randomized, multi-centre, non-inferiority trial is to to determine whether knee-joint distraction (KD) is non-inferior on patient reported effectiveness as compared to a knee-prosthesis (KP; i.e. usual care) for relatively young patients with end-stage knee Osteoarthritis (OA).

The main question[s] it aims to answer are:
  • Is KD non-inferior to KP regarding pain, function and stiffness (as indicated by the total score on the total Western Ontario and McMaster Universities Osteoarthritis Index' (WOMAC), with a non-inferiority limit of 15 points) at 2 years?

  • Is KD non-inferior to KP regarding Quality of Life (36-Item Short Form Health Survey, (SF36), Physical- and Mental- Component Summary (PCS/MCS), with a non-inferiority limit of 10 points) at 2 years?

  • Does KD lead to regeneration of tissue (increase in minimum joint-space-width > 0.05mm on x-ray) over 2 years?

Participants will be allocated to undergo either a knee joint distraction or prosthesis (total- or unicompartmental KP according to orthopedic surgeon/patients discretion), and groups will be compared using will be compared between groups using (multivariable) random effects (mixed) modelling to account for the nested and longitudinal structure of the data over the 24 months follow-up. The stratification factors for randomization, center (using a random intercept) and gender, as well as a limited number of a priori defined prognostic factors (i.e. baseline WOMAC total score, age, BMI, severity of cartilage damage) will be accounted for in this analysis. The difference in mean total WOMAC score at 24 months between treatment groups will be estimated from this model with a 95% confidence interval (CI) and non-inferiority will be determined using the lower limit of this confidence interval.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Knee Joint Distraction (KD)
  • Procedure: Knee Prosthesis
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
600 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Grip on Knee Osteoarthritis; DIstraction Versus Arthroplasty (GODIVA) for Young Knee Osteoarthritis Patients in Regular Care
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2028
Anticipated Study Completion Date :
Jun 1, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Knee Joint Distraction (KD)

Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame. KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.

Procedure: Knee Joint Distraction (KD)
Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame.KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.

Active Comparator: Knee Prosthesis

KP is indicated and surgically implanted according to regular clinical practice (can be a total- or unicompartmental KP, in line with local practice in consultation with the patient and conform the national guideline by Dutch orthopaedic society (NOV)).

Procedure: Knee Prosthesis
A total or unicompartmental knee prosthesis

Outcome Measures

Primary Outcome Measures

  1. WOMAC total Score [at 24 months]

    Western Ontario and McMaster Universities Osteoarthritis Index' (WOMAC) total score (scale 0-100, higher scores indicate improvement), with a non-inferiority limit of 15 points

Secondary Outcome Measures

  1. Health Related Quality of Life (HRQol) [24 months]

    SF36 physical component score and mental component score (0-100)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical diagnosis of knee OA

  • Age ≤ 65 years and ≥ 18 years

  • Persistent, refractory pain, insufficiently responding to conservative or previous surgical therapy

  • Structural OA joint damage, indicated by a K&L grade of at least 2 as determined by the orthopedic surgeon in line with NOV recommendations.

  • Able to wear an external fixator and care for it for 6 weeks

  • Accepting that the maximal effect of KJD is not present directly after removal of the frame but may take months after frame removal

  • Sufficient joint stability (according to the orthopedic surgeon's judgement)

  • Flexion (>100 degrees) and extension range (<10 degrees)

  • Weight and BMI <120 kg and <35 kg/m2, respectively

  • Sufficient understanding of the Dutch language

  • Signed informed consent

Exclusion criteria:
  • Surgical intervention in last 6 months

  • Leg-axis deviation > 10 degrees (as determined by the orthopedic surgeon)

  • Serious osteopenia making placing bone-pins and wearing a frame into a risk (according to the orthopedic surgeon's judgement)

  • Coagulation problems making occurrence of thrombosis or embolies into a risk (according to the orthopedic surgeon's judgement)

  • Existing endoprosthesis at any other joint (e.g. hip or contralateral knee) to prevent infection of existing prosthesis

  • History or presence of joint infection/inflammation

  • Hypersensitivity to antibiotics

  • Presence of systemic inflammatory disease, like rheumatoid arthritis

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • UMC Utrecht

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Paco M.J. Welsing, Associate Professor, UMC Utrecht
ClinicalTrials.gov Identifier:
NCT06113549
Other Study ID Numbers:
  • 22-732/G
First Posted:
Nov 2, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Paco M.J. Welsing, Associate Professor, UMC Utrecht
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 7, 2023